- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05309421
절제불가능 또는 전이성 흑색종 성인 환자에서 EVX-01과 Pembrolizumab 병용요법의 효능 및 안전성을 평가하는 단일군 임상시험
절제 불가능 또는 전이성 흑색종을 가진 순진한 성인을 대상으로 관문 억제제 치료에서 EVX-01과 펨브롤리주맙을 병용하여 효능 및 안전성을 평가하는 공개 라벨, 단일군 임상시험
The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab alone.
연구 개요
상세 설명
Patients will initiate treatment with pembrolizumab at the start of the trial and receive up to 18 treatment cycles (approximately 2 years). Immunization with the EVX-01 will be initiated at Week 12. In total, 10 doses of EVX-01 will be administered intramuscularly, with 6 doses given two weeks apart and 4 booster doses at later time points.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Italy
-
Milan, Italy, 이탈리아
- Divisione di Oncologia Medica del Melanoma
-
Naples, Italy, 이탈리아
- Instituto Nazionale Tumori IRCCS Fondazione
-
-
-
-
New South Wales
-
Wollstonecraft, New South Wales, 호주, 2065
- Melanoma Institute Australia
-
-
Western Australia
-
Nedlands, Western Australia, 호주, 6009
- One Clinical Research
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Be at least 18 years of age on day of signing informed consent.
-
Histologically confirmed, and not amenable to local therapy, metastatic or unresectable melanoma Stage III or Stage IV, as per AJCC 8th ed. staging system.
- Patient may not have a diagnosis of uveal or ocular melanoma.
- Patients must be treatment naïve to checkpoint inhibitor (CPI) therapy
- Patients must have testing for a BRAF mutation prior to study entry.
Note: Patients with BRAF V600E mutant melanoma may have received prior BRAF inhibitor therapy as first-line systemic therapy and be eligible for this study as second line treatment. At the discretion of the investigator, patients with BRAF V600E mutant melanoma who have NOT received a BRAF inhibitor are also eligible for this study as first line treatment if they meet the following additional criteria:
i. LDH < local ULN, ii. No clinically significant tumor related symptoms in the judgment of the investigator, and iii. Absence of rapidly progressing metastatic melanoma in the judgment of the investigator
- Have measurable disease per RECIST 1.1 as assessed by the local site investigator within 4 weeks prior to the first visit. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- Patients must be willing and able to provide fresh or frozen tumor tissue from an unresectable or metastatic site of disease for neoepitope and biomarker analyses. If a sufficient amount of tumor tissue from an unresectable or metastatic site is not available prior to the start of the screening phase, subjects must consent to allow the acquisition of additional tumor tissue. In addition, participants may provide additional biopsy at the time of discontinuation due to progression.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
- Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.
- Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
- Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Administration of killed vaccines are allowed.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: EVX-01 in combination with pembrolizumab
EVX-01 is administered im. Pembrolizumab is administered according to label |
Investigational drug given in combination with standard of care Standard of care
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in the best overall response (BOR)
기간: Measurements at Baseline through study completion (up to 102 weeks)
|
Composite of a BOR of complete response (CR) or PR for patients with SD at the time of first EVX-01 administration and a BOR of CR for patients with PR at the time of first EVX-01 administration, within 2 years of treatment with pembrolizumab, as per RECIST 1.1 criteria |
Measurements at Baseline through study completion (up to 102 weeks)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in overall response rate
기간: Measurements at Baseline through study completion (up to 102 weeks)
|
Overall response rate, defined as the proportion of the patients who have best response as CR or PR assessed 2 years after initiation of treatment with pembrolizumab, as per RECIST 1.1 criteria |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Change in progression free survival (PFS)
기간: Measurements at Baseline through study completion (up to 102 weeks)
|
PFS in patients with an assessment of SD, PR, or CR at the time of first EVX-01 administration, assessed 2 years after initiation of treatment with pembrolizumab and defined as the time from the first EVX-01 administration to the first documented disease progression per RECIST 1.1. criteria or death due to any causes, whichever occurs first |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Change in overall survival (OS)
기간: Measurements at Baseline through study completion (up to 102 weeks)
|
OS assessed 2 years after initiation of treatment with pembrolizumab and defined as the time from initiation of treatment of pembrolizumab to death due to any cause |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Number, type and severity of adverse events (AEs) and serious adverse events (SAEs)
기간: Measurements at Baseline through study completion (up to 102 weeks)
|
Number, type and severity of adverse events (AEs) and serious adverse events (SAEs) |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Immunologic response induced by EVX-01
기간: Measurements at Baseline through study completion (up to 102 weeks)
|
Activation and level of neoepitope specific T-cells before, during and after EVX-01 immunization |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Percentage of patients in which EVX-01 is generated, produced, and administered
기간: From tumor biopsy sampling to first dose of EVX-01 (up to 16 weeks)
|
Percentage of patients in which EVX-01 is generated, produced, and administered |
From tumor biopsy sampling to first dose of EVX-01 (up to 16 weeks)
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- EVX-01-001
- KEYNOTE-D36 (기타 식별자: Merck Sharp & Dohme Corp.)
- 2024-512393-10-00 (씨티스)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .